<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02110420</url>
  </required_header>
  <id_info>
    <org_study_id>CC-90001-CP-001</org_study_id>
    <nct_id>NCT02110420</nct_id>
  </id_info>
  <brief_title>First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001</brief_title>
  <official_title>A Phase 1, Randomized, Two-part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-in-human study to evaluate safety, tolerability, and pharmacokinetics of single and&#xD;
      multiple ascending doses of CC-90001&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-part study to be conducted at a single study center. Part 1 is a randomized,&#xD;
      double-blind, placebo-controlled study to evaluate the safety, tolerability, and&#xD;
      pharmacokinetics of CC-90001 following a single oral dose in healthy subjects. During the&#xD;
      course of Part 1, each subject will participate in a screening phase, a baseline phase, a&#xD;
      treatment phase and a follow up visit. There will be a total of 7 planned cohorts, each of&#xD;
      which will consist of a different dose level, with 8 subjects per cohort. In each cohort, 6&#xD;
      subjects will receive a dose of CC 90001 and 2 subjects will receive placebo depending on the&#xD;
      randomization schedule. Administration of study drug at the next higher dose level will not&#xD;
      begin until the safety and tolerability of the preceding dose have been evaluated and deemed&#xD;
      acceptable by the investigator and sponsor's medical monitor. Part 2 is a randomized,&#xD;
      double-blind, placebo-controlled study to evaluate the safety, tolerability, and&#xD;
      pharmacokinetics of CC-90001 following multiple oral doses in healthy subjects. Only doses&#xD;
      that are safe and well tolerated in Part 1 will be administered in Part 2. During the course&#xD;
      of Part 2, each subject will participate in a screening phase, a baseline phase, a treatment&#xD;
      phase and a follow up visit. There will be a total of up to 6 planned cohorts, each of which&#xD;
      will consist of a different dose level, with 8 subjects per cohort. In each cohort, 6&#xD;
      subjects will receive a dose of CC 90001 and 2 subjects will receive placebo depending on the&#xD;
      randomization schedule. It is planned for study drug to be administered once daily for up to&#xD;
      14 days. Proposed dose levels in Part 2 may be modified and/or eliminated based on data&#xD;
      obtained from Part 1; however, the maximum dose administered in Part 2 will not exceed the&#xD;
      maximum tolerated dose in Part 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 8 months overall</time_frame>
    <description>Number of participants with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of CC-90001 in plasma</measure>
    <time_frame>Up to 14 days per cohort</time_frame>
    <description>Blood samples will be collected at pre-specified times to determine levels of CC-90001 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum observed plasma concentration</measure>
    <time_frame>Up to 14 days per cohort</time_frame>
    <description>Cmax will be estimated for CC-90001 using a non-compartmental approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Cmax</measure>
    <time_frame>Up to 14 days per cohort</time_frame>
    <description>Tmax will be estimated for CC-90001 using a non-compartmental approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf: Area under the plasma concentration-time curve from time zero extrapolated to infinity</measure>
    <time_frame>Up to 14 days per cohort</time_frame>
    <description>AUCinf will be estimated for CC-90001 using a non-compartmental approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt: Area under the plasma concentration-time curve from time zero to the last quantifiable concentration</measure>
    <time_frame>Up to 14 days per cohort</time_frame>
    <description>AUCt will be estimated for CC-90001 using a non-compartmental approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau: Area under the plasma concentration-time curve from time zero to tau, where tau is the dosing interval</measure>
    <time_frame>Up to 14 days per cohort</time_frame>
    <description>AUCtau will be estimated for CC-90001 using a non-compartmental approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau will be estimated for CC-90001 using a non-compartmental approach</measure>
    <time_frame>Up to 14 days per cohort</time_frame>
    <description>t1/2,z will be estimated for CC-90001 using a non-compartmental approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Apparent total plasma clearance when dosed orally</measure>
    <time_frame>Up to 14 days per cohort</time_frame>
    <description>CL/F will be estimated for CC-90001 using a non-compartmental approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F: Apparent total volume of distribution when dosed orally, based on the terminal phase</measure>
    <time_frame>Up to 14 days per cohort</time_frame>
    <description>Vz/F will be estimated for CC-90001 using a non-compartmental approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Accumulation based on Day 1 and Day 14 AUCtau</measure>
    <time_frame>Up to 14 days per cohort</time_frame>
    <description>Ratio of accumulation will be estimated for CC-90001 using a non-compartmental approach</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>CC-90001 10mg (Single Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 30mg (Single Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 60mg (Single Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 120mg (Single Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 240mg (Single Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 10mg (Multiple Doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 30mg (Multiple Doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 60mg (Multiple Doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 120mg (Multiple Doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 240mg (Multiple Doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 480mg (single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-90001 480mg will be administered as a single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 720mg (single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-90001 720mg will be administered as a single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-90001 480mg (multiple doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-90001 480mg will be administered daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001 10mg will be administered as a single dose</description>
    <arm_group_label>CC-90001 10mg (Single Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001 30mg will be administered as a single dose</description>
    <arm_group_label>CC-90001 30mg (Single Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001 60mg will be administered as a single dose</description>
    <arm_group_label>CC-90001 60mg (Single Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001 120mg will be administered as a single dose</description>
    <arm_group_label>CC-90001 120mg (Single Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001 240mg will be administered as a single dose</description>
    <arm_group_label>CC-90001 240mg (Single Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001 10mg will be administered daily for 14 days</description>
    <arm_group_label>CC-90001 10mg (Multiple Doses)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001 30mg will be administered daily for 14 days</description>
    <arm_group_label>CC-90001 30mg (Multiple Doses)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001 60mg will be administered daily for 14 days</description>
    <arm_group_label>CC-90001 60mg (Multiple Doses)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001 120mg will be administered daily for 14 days</description>
    <arm_group_label>CC-90001 120mg (Multiple Doses)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001 240mg will be administered daily for 14 days</description>
    <arm_group_label>CC-90001 240mg (Multiple Doses)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered once daily for up to 14 days depending on the Part of the study</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001 480mg will be administered as a single oral dose</description>
    <arm_group_label>CC-90001 480mg (single dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001 720mg will be administered as a single oral dose</description>
    <arm_group_label>CC-90001 720mg (single dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90001</intervention_name>
    <description>CC-90001 480mg will be administered daily for 14 days</description>
    <arm_group_label>CC-90001 480mg (multiple doses)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Must understand and voluntarily sign a written informed consent prior to any&#xD;
             study-related procedures being performed.&#xD;
&#xD;
             2. Must be able to communicate with the investigator, understand and comply with the&#xD;
             requirements of the study, and agree to adhere to restrictions and examination&#xD;
             schedules.&#xD;
&#xD;
             3. Healthy male or female of any race between 18 to 50 years of age (inclusive) at the&#xD;
             time of signing the informed consent, and in good health as determined by a physical&#xD;
             examination at screening.&#xD;
&#xD;
             4. For males: Agree to use barrier contraception not made of natural (animal) membrane&#xD;
             [for example, latex or polyurethane condoms are acceptable]) when engaging in sexual&#xD;
             activity with a female of childbearing potential while on study medication, and for at&#xD;
             least 28 days after the last dose of study medication.&#xD;
&#xD;
        For females: Female subjects must have been surgically sterilized (hysterectomy or&#xD;
        bilateral oophorectomy; proper documentation required) at least 6 months before screening,&#xD;
        or be postmenopausal (defined as 24 months without menses before screening, with an&#xD;
        estradiol level of &lt; 30 pg/mL and follicle-stimulating hormone level of &gt; 40 IU/L at&#xD;
        screening).&#xD;
&#xD;
        5. Must have a body mass index between 18 and 33 kg/m2 (inclusive). 6. Platelet count,&#xD;
        absolute neutrophil count and absolute lymphocyte count must be above the lower limit of&#xD;
        normal at the screening visit.&#xD;
&#xD;
        7. Liver function tests must be below the upper limit of normal at screening. 8. All other&#xD;
        clinical laboratory tests must be within normal limits or acceptable to the investigator.&#xD;
&#xD;
        9. Subject must be afebrile, with supine systolic blood pressure: 90 to 140 mmHg, supine&#xD;
        diastolic blood pressure: 50 to 90 mmHg, and pulse rate: 40 to 110 bpm at screening.&#xD;
&#xD;
        10. Must have a normal or clinically-acceptable 12-lead electrocardiogram at screening.&#xD;
        Male subjects must have a QTcF value ≤ 430 msec. Female subjects must have a QTcF value ≤&#xD;
        450 msec.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History of any clinically significant and relevant neurological, gastrointestinal,&#xD;
             renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine,&#xD;
             hematological, allergic disease, drug allergies, or other major disorders.&#xD;
&#xD;
             2. Any condition which places the subject at unacceptable risk if he or she were to&#xD;
             participate in the study, or confounds the ability to interpret data from the study.&#xD;
&#xD;
             3. Exposed to an investigational drug (new chemical entity) within 30 days preceding&#xD;
             the first dose administration, or 5 half-lives of that investigational drug, if known&#xD;
             (whichever is longer).&#xD;
&#xD;
             4. Used any prescribed systemic or topical medication (including but not limited to&#xD;
             analgesics, anesthetics, etc) within 30 days of the first dose administration.&#xD;
&#xD;
             5. Used any non-prescribed systemic or topical medication (including vitamin/mineral&#xD;
             supplements, and herbal medicines) within 14 days of the first dose administration.&#xD;
&#xD;
             6. Used cytochrome P450 (CYP)3A inducers and inhibitors (including St. John's Wort)&#xD;
             within 30 days of the first dose administration.&#xD;
&#xD;
             7. Has any surgical or medical conditions possibly affecting drug absorption,&#xD;
             distribution, metabolism and excretion, for example, bariatric procedure. Appendectomy&#xD;
             and cholecystectomy are acceptable.&#xD;
&#xD;
             8. Donated blood or plasma within 8 weeks before the first dose administration to a&#xD;
             blood bank or blood donation center.&#xD;
&#xD;
             9. History of drug abuse (as defined by the current version of the Diagnostic and&#xD;
             Statistical Manual) within 2 years before dosing, or positive drug screening test&#xD;
             reflecting consumption of illicit drugs.&#xD;
&#xD;
             10. History of alcohol abuse (as defined by the current version of the Diagnostic and&#xD;
             Statistical Manual) within 2 years before dosing, or positive alcohol screen.&#xD;
&#xD;
             11. Known to have serum hepatitis or known to be a carrier of hepatitis B surface&#xD;
             antigen or hepatitis c antibody, or have a positive result to the test for human&#xD;
             immunodeficiency virus antibodies at screening.&#xD;
&#xD;
             12. Smoke more than 10 cigarettes per day, or the equivalent in other tobacco products&#xD;
             (self reported).&#xD;
&#xD;
             13. History of ulcerative colitis, Crohn's disease, diverticular disease, any polyp(s)&#xD;
             along the gastrointestinal tract, or colorectal cancer.&#xD;
&#xD;
             14. History of hemorrhoids, anal fissures, rectal ulcers, minor rectal bleeding (such&#xD;
             as red blood on toilet paper after wiping) within 5 years before the first dose&#xD;
             administration.&#xD;
&#xD;
             15. History of gastrointestinal bleeding or blood in stool within 5 years before the&#xD;
             first dose administration.&#xD;
&#xD;
             16. Any positive fecal occult blood test at screening and/or at any time prior to&#xD;
             first dosing.&#xD;
&#xD;
             17. Any history of constipation within 2 years before the first dose administration.&#xD;
&#xD;
             18. Subject does not routinely have a bowel movement, at minimum, every third day.&#xD;
&#xD;
             19. Any subject with a history of Irritable Bowel Syndrome or a history of frequent&#xD;
             abdominal cramping, frequent diarrhea, or frequent loose stools (with frequent defined&#xD;
             as once per week or greater).&#xD;
&#xD;
             20. Any female subject with menses (natural or artificial). 21. Any subject taking&#xD;
             hormonal contraception. 22. Subjects who are part of the clinical staff personnel or&#xD;
             family members of the clinical site staff.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Weiss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy Subjects</keyword>
  <keyword>First-in-Human</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

